NIAID Reflects on a Productive 2016

As 2017 approaches, a new slideshow highlights notable scientific accomplishments made by NIAID laboratories and NIAID-funded scientists during fiscal year 2016. Among many advances, NIAID research drove progress toward development of vaccines and treatments for HIV, flu, Zika, and other infectious diseases of global importance. Researchers also made discoveries yielding new insights into food allergy prevention, autoimmune diseases, and drug-resistant infections.

Selected NIAID Research Advances of 2016

Message from the Director

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

This slideshow highlights scientific advances made by NIAID researchers and NIAID-funded scientists in the United States and abroad during fiscal year 2016. Some advances brought us closer to vaccines and treatments for HIV/AIDS, Zika, influenza, and other infectious diseases of global importance. Other developments offered new insights into allergic and autoimmune diseases, and immune responses to infection. Together, these advances illustrate how public investment in biomedical research drives scientific progress and benefits human health.

For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. Through our sustained commitment to basic and clinical research, we will continue to address global health challenges for years to come.

Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health